
users worldwide
curated findings
new data findings/day
patient tests analyzed
Real time access and analysis of over 40 genomic and clinical databases covering over 33,000 diseases.
Join us at an event or attend a webinar to learn how our products, solutions and services are empowering customers around the world to unlock valuable molecular insights.
Evidence based research, services and advanced software for better decisions.
Have you reserved your in-person or virtual spot at the European Human Genetics Conference (ESHG) he...
The latest COSMIC Actionability release is here with a focus on the ERBB2 gene. Before we delve into...
Do you ever struggle to formulate hypotheses based on your experimental expression data? You may be ...
More mutations, better annotations, confident classifications HGMD Professional 2022.1 is now av...
You need biomedical relationships knowledge for innovative data- and analytics-driven drug discovery...
Scale your exome workflow with Dr. Atil Bisgin at ESHG 2022
How to track the progress of ERBB2-targeted therapies from early case studies to market with COSMIC Actionability
Three easy ways to process your expression data to gain biological insights
New Content Release: HGMD Professional 2022.1
Accelerate your data science-driven drug discovery: Announcing QIAGEN Biomedical Knowledge Base
Targeted NGS panels and optimized analysis and interpretation tools.
Discovery Bioinformatics Services is a reliable and convenient way to extend your in-house resources with expertise and perfectly tailored bioinformatics services that ensure high-quality results.
Enabling pharma companies to develop biomarker diagnostics and targeted therapies using real-world insights from oncology patient genomic data.
Helping clinical testing laboratories leverage the benefits of automation and expert support to improve test turnaround times, enhance clinical reporting capabilities and scale for future growth.
QIAGEN maintains the world’s largest, expert-curated knowledgebase of up-to-date evidence for discovery research, clinical test interpretation and pharmaceutical development.
In Germany, scientists tackle cancer cohorts with Sample to Insight QIAGEN tools.